Sajja Venkatesh on the Results of CREST-2 Trial
Sajja Venkatesh, Interventional Neurologist, FNB-NeuroVascular Intervention at Apollo Hospitals, shared on LinkedIn:
”CREST-2 Trial: Carotid artery stenting (CAS) vs Carotid Endarterectomy (CEA) for asymptomatic high-grade carotid stenosis (≥70%) who have not had recent stroke symptoms,
- Addition of CAS resulted in a reduced risk of a composite of perioperative stroke, death, or ipsilateral stroke within a 4 year timeframe, surpassing the outcomes achieved through intensive medical management alone.
- Conversely, CEA did not demonstrate a statistically significant advantage.
Primary Outcome:
– Stenting Trial: The 4-year incidence of stroke or death was significantly lower in the stenting group (2.8%) compared to the medical-therapy group (6.0%), with an absolute risk reduction of 3.2 percentage points (P=0.02).
– Endarterectomy Trial: No significant difference was observed between the endarterectomy group (3.7%) and the medical-therapy group (5.3%) (P=0.24).”
Read the full article here.
Article: Medical Management and Revascularization for Asymptomatic Carotid Stenosis
Authors: CREST-2 Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 00:23Saji Kumar: The Role of Agentic AI in Blood Bank Inventory Coordination
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders